nach oben

Erschienen in:

13.12.2016 | fortbildung

Advanced Glycation Endproducts

Diabetesscreening und Risikocheck über die Autofluoreszenz der Haut

verfasst von: PD Dr. med. Ovidiu Alin Stirban

Erschienen in: Info Diabetologie | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Messung der Akkumulation der Advanced Glycation Endproducts (AGEs) erlaubt Rückschlüsse auf den Glukosestoffwechsel mehrerer Jahre und könnte die Aussage des HbA_1c-Wertes ergänzen. AGEs können mit einer einfachen Methode, die auf der Messung der Autofluoreszenz der Haut (AFH) basiert, nicht invasiv und rasch an der Hautoberfläche gemessen werden. Studien deuten darauf hin, dass die AFH das Screening auf Diabetes und vaskuläre Folgekomplikationen verbessern könnte.

Aiello LP; DCCT/EDIC Research Group. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37: 17–23, 2014CrossRefPubMed

Aroda VR, Conway BN, Fernandez SJ, Matter NI, Maynard JD, Orchard TJ, Ratner RE: Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes. Diabetes Technol Ther 15:117–123, 2013CrossRefPubMedPubMedCentral

Chabroux S, Canoui-Poitrine F, Reffet S, Mills-Joncour G, Morelon E, Colin C, Thivolet C: Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Diabetes Metab 36:152–157, 2010CrossRefPubMed

Cleary, PA, Braffett, BH, Orchard, T, Lyons, TJ, Maynard, J, Gubitosi-Klug, RA, Way, J, Anderson, K, Barnie, A, Villavicencio, S, and and the DCCT/EDIC Research Group. Clinical and Technical Factors Associated with Skin Intrinsic Fluorescence in Subjects with Type 1 Diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Technology & Therapeutics 15, 466–474. 2013.CrossRef

Conway B, Edmundowicz D, Matter N, Maynard J, Orchard T: Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes. Diabetes Technol Ther 12:339–345, 2010CrossRefPubMedPubMedCentral

Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, Ratner RE, Orchard TJ: Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes. Diabetes Care 34:1000–1005, 2011CrossRefPubMedPubMedCentral

Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, Ratner RE, Orchard TJ: Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care 35:2331–2336, 2012CrossRefPubMedPubMedCentral

de Ranitz-Greven WL, Kaasenbrood L, Poucki WK, Hamerling J, Bos DC, Visser GH, Biesma DH, Beulens JW, de Valk HW: Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitus. Diabetes Technol Ther 14:1134–1139, 2012CrossRefPubMed

de Vos LC, Noordzij MJ, Mulder DJ, Smit AJ, Lutgers HL, Dullaart RP, Kamphuisen PW, Zeebregts CJ, Lefrandt JD: Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease. Arterioscler Thromb Vasc Biol 33:131–138, 2013CrossRefPubMed

10.

Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54:3103–3111, 2005CrossRefPubMedPubMedCentral

11.

Gerrits EG, Lutgers HL, Kleefstra N, Groenier KH, Smit AJ, Gans RO, Bilo HJ: Skin advanced glycation end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC-9). J Diabetes Sci Technol 2:572–577, 2008CrossRefPubMedPubMedCentral

12.

Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ: Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 31:517–521, 2008CrossRefPubMed

13.

Gerrits EG, Lutgers HL, Smeets GH, Groenier KH, Smit AJ, Gans RO, Bilo HJ: Skin autofluorescence: a pronounced marker of mortality in hemodialysis patients. Nephron Extra 2:184–191, 2012CrossRefPubMedPubMedCentral

14.

Gubitosi-Klug. The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care 2016 May;39(5):686–93.CrossRef

15.

Hartog JW, de Vries AP, Lutgers HL, Meerwaldt R, Huisman RM, van Son WJ, de Jong PE, Smit AJ: Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 1043:299–307, 2005CrossRefPubMed

16.

Hartog JW, de Vries AP, Bakker SJ, Graaff R, van Son WJ, van der Heide JJ, Gans RO, Wolffenbuttel BH, de Jong PE, Smit AJ: Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Nephrol Dial Transplant 21:2263–2269, 2006CrossRefPubMed

17.

Hartog JW, Gross S, Oterdoom LH, van Ree RM, de Vries AP, Smit AJ, Schouten JP, Nawroth PP, Gans RO, van Son WJ, Bierhaus A, Bakker SJ: Skin-autofluorescence is an independent predictor of graft loss in renal transplant recipients. Transplantation 87:1069–1077, 2009CrossRefPubMed

18.

Hofmann B, Adam AC, Jacobs K, Riemer M, Erbs C, Bushnaq H, Simm A, Silber RE, Santos AN: Advanced glycation end product associated skin autofluorescence: a mirror of vascular function? Exp Gerontol 48:38–44, 2013CrossRefPubMed

19.

Januszewski AS, Sachithanandan N, Karschimkus C, O’Neal DN, Yeung CK, Alkatib N, Jenkins AJ: Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet Med 29:726–733, 2012CrossRefPubMed

20.

Kitahara T, Ono K, Tsuchida A, Kawai H, Shinohara M, Ishii Y, Koyanagi H, Noguchi T, Matsumoto T, Sekihara T, Watanabe Y, Kanai H, Ishida H, Nojima Y: Impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on mortality in hemodialysis patients. Am J Kidney Dis 46:688–696, 2005CrossRefPubMed

21.

Kessel L, Hougaard JL, Sander B, Kyvik KO, Sorensen TI, Larsen M: Lens ageing as an indicator of tissue damage associated with smoking and non-enzymatic glycation—a twin study. Diabetologia 45:1457–1462, 2002CrossRefPubMed

22.

Koefoed TP, Hansen T, Larsen M, Pedersen O, Lund-Andersen H: Lens autofluorescence is increased in newly diagnosed patients with NIDDM. Diabetologia 39:1524–1527, 1996CrossRef

23.

Koetsier M, Lutgers HL, de JC, Links TP, Smit AJ, Graaff R: Reference values of skin autofluorescence. Diabetes Technol Ther 12:399–403, 2010CrossRefPubMed

24.

Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94:6474–6479, 1997CrossRef

25.

Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 64: 631–642, 2015CrossRefPubMed

26.

Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 29:2654–2659, 2006CrossRefPubMed

27.

Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ: Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 52:789–797, 2009CrossRefPubMed

28.

Lutgers HL, Graaff R, de VR, Smit AJ, Dullaart RP: Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically manifest cardiovascular disease. Eur J Clin Invest 40:812–817, 2010CrossRefPubMed

29.

Lyons TJ, Bailie KE, Dyer DG, Dunn JA, Baynes JW: Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 87:1910–1915, 1991CrossRefPubMedPubMedCentral

30.

Martin CL, Albers JW, Pop-Busui R; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37:31–38, 2014CrossRefPubMed

31.

Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN: Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care 30:1120–1124, 2007CrossRefPubMed

32.

McIntyre NJ, Chesterton LJ, John SG, Jefferies HJ, Burton JO, Taal MW, Fluck RJ, McIntyre CW: Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 5:51–55, 2010CrossRefPubMedPubMedCentral

33.

McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW: Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol 6:2356–2363, 2011CrossRefPubMedPubMedCentral

34.

Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ: Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47:1324–1330, 2004CrossRefPubMed

35.

Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J, Gans R, Smit A: Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 1043:290–298, 2005CrossRefPubMed

36.

Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ: Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 48:1637–1644, 2005CrossRefPubMed

37.

Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16:3687–3693, 2005CrossRefPubMed

38.

Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ: Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30:107–112, 2007CrossRefPubMed

39.

Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314:403–408, 1986CrossRefPubMed

40.

Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S: Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 48:870–880, 1999CrossRefPubMedPubMedCentral

41.

Mulder DJ, van Haelst PL, Gross S, de LK, Bijzet J, Graaff R, Gans RO, Zijlstra F, Smit AJ: Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 197:217–223, 2008CrossRefPubMed

42.

Mulder DJ, van Haelst PL, Graaff R, Gans RO, Zijlstra F, Smit AJ: Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth Heart J 17:162–168, 2009CrossRefPubMedPubMedCentral

43.

Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ: Skin autofluorescence and glycemic variability. Diabetes Technol Ther 12:581-585, 2010

44.

Noordzij MJ, Lefrandt JD, Loeffen EA, Saleem BR, Meerwaldt R, Lutgers HL, Smit AJ, Zeebregts CJ: Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Int J Cardiovasc Imaging 28:431–438, 2012CrossRefPubMed

45.

Noordzij MJ, Mulder DJ, Oomen PH, Brouwer T, Jager J, Castro CM, Lefrandt JD, Smit AJ: Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study. Diabet Med 29:1556–1561, 2012CrossRefPubMed

46.

Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM, Albers JW: DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 10:276–282, 2010CrossRefPubMedPubMedCentral

47.

Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ: The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 39:946–951, 1996CrossRefPubMed

48.

Smit AJ, Gerrits EG: Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 19:527–533, 2010CrossRefPubMed

49.

Smit AJ, Smit JM, Botterblom GJ, and Mulder DJ. Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes. PLOS ONE 8(6):e65592, 2013.CrossRefPubMedPubMedCentral

50.

Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D: Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29:2064–2071, 2006CrossRefPubMed

51.

Stirban A, Pop A, Fischer A, Heckermann S, and Tschoepe D. Variability of Skin Autofluorescence Measurement Over 6 and 12 Weeks and the Influence of Benfotiamine Treatment. Diabetes Technology and Therapeutics 15:733–7, 2013.CrossRefPubMed

52.

Sugisawa E, Miura J, Iwamoto Y, Uchigata Y: Skin Autofluorescence Reflects Integration of Past Long-Term Glycemic Control in Patients With Type 1 Diabetes. Diabetes Care 36:2339–45, 2013CrossRefPubMedPubMedCentral

53.

Tentolouris N, Lathouris P, Lontou S, Tzemos K, Maynard J: Screening for HbA1c-defined prediabetes and diabetes in an at-risk greek population: Performance comparison of random capillary glucose, the ADA diabetes risk test and skin fluorescence spectroscopy. Diabetes Res Clin Pract 100:39–45, 2013CrossRefPubMed

54.

van den Oord SC, Sijbrands EJ, Ten Kate GL, van KD, van Domburg RT, van der Steen AF, Schinkel AF: Carotid intima-media thickness for cardiovascular risk assessment: Systematic review and meta-analysis. Atherosclerosis 228:1–11, 2013CrossRefPubMed

55.

Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T, Emoto M, Tahara H, Kakiya R, Tabata T, Miyata T, Nishizawa Y: Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 57:1452–1457, 2008CrossRefPubMed

56.

Vlassara H, Uribarri J: Glycoxidation and diabetic complications: modern lessons and a warning? Rev Endocr Metab Disord 5:181–188, 2004CrossRefPubMed

57.

Vlassara H: Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 1043:452–460, 2005CrossRefPubMed

58.

Vlassara H and Striker G. The role of AGE-products in the etiology of insulin resistance and diabetes. US Endocrinology 6, 14–19. 2010.CrossRef

59.

Watfa G, Soulis G, Tartagni E, Kearney-Schwartz A, Borghi C, Salvi P, Benetos A: Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations. Diabetes Metab 38:413–419, 2012CrossRefPubMed

60.

Weiss MF, Erhard P, Kader-Attia FA, Wu YC, Deoreo PB, Araki A, Glomb MA, Monnier VM: Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 57:2571–2585, 2000CrossRefPubMed

61.

Yue X, Hu H, Koetsier M, Graaff R, Han C: Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue. Diabet Med 28:818–823, 2011CrossRefPubMed

Titel: Advanced Glycation Endproducts
Diabetesscreening und Risikocheck über die Autofluoreszenz der Haut
verfasst von: PD Dr. med. Ovidiu Alin Stirban
Publikationsdatum: 13.12.2016
Verlag: Springer Medizin
Erschienen in: Info Diabetologie / Ausgabe 6/2016
Print ISSN: 1865-5459
Elektronische ISSN: 2196-6362
DOI: https://doi.org/10.1007/s15034-016-0995-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diabetesscreening und Risikocheck über die Autofluoreszenz der Haut

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Weniger Hypoglykämie mit Flash-Glukose-Messung

Sicherheit geht vor Wirksamkeit

Bewerbungsfrist bis 31.12.2016 verlängert!

Oft schon in den Augen zu sehen

Kohlenhydrate bedarfsgerecht zuführen

Neues Insulin contra BZ-Spitzen ante portas

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin